Beeline Medicines

Biotech developing precision therapies for autoimmune and inflammatory diseases, built around five immunology assets from Bristol Myers Squibb.

View on the globe

$426MEquity raised in 2025–20262025 — · 2026 $426M · 1 equity round
$426MEquity raised, all time1 equity round on record
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 15 Apr 2026 to 15 Apr 2026, $426M equity disclosed.15 Apr 2026: Series A, $426M$10M$30M$100M$300M$1BQ42026Q2Q3Q42027Equity round15 Apr 2026 · Series A · $426M · led by Bain CapitalSeries A · $426M
Funding history: 1 round from 15 Apr 2026 to 15 Apr 2026, $426M equity disclosed.15 Apr 2026: Series A, $426M$10M$30M$100M$300M$1BQ42026Q2Q3Q42027Equity round15 Apr 2026 · Series A · $426M · led by Bain Capital$426M

Funding history 1 round · 3 sources

  1. Series A
    Amount$426M
    Post-money—
    ✓ Confirmed
    Lead
    Bain Capital
    Also
    CPP Investments, Bristol Myers Squibb
    Note
    Initial $300M Series A led by Bain Capital announced 2026-04-15; extended by $126.3M on 2026-06-30 (Bain Capital, CPP Investments, Bristol Myers Squibb and others) to $426.3M total, recorded as one round.
    Sources

Investors 3

  • Bain Capital1
  • Bristol Myers Squibb
  • CPP Investments

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Beeline Medicines and its logo are trademarks of their owners, used here for identification only.